Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Rituximab combination therapy for waldenström’s macroglobulinemia

Jithma Abeykoon • 2 Jun 2019
ASCO 2019
Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Bendamustine Dexamethasone Rituximab

Jithma Abeykoon, MD, PhD, of the Mayo Clinic, Rochester, MN, gives an overview of rituximab-based combination therapy outcomes in patients with waldenström’s macroglobulinemia. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Jithma Abeykoon

2:15
Waldenström’s macroglobulinemia: what options are available?
Jithma Abeykoon • 3 Jun 2019
1:21
Individualized therapy in waldenström’s macroglobulinemia
Jithma Abeykoon • 3 Jun 2019
Real world ibrutinib efficacy for Waldenström's macroglobulinemia
Jithma Abeykoon • 5 Dec 2018
Improving the accuracy of Waldenström’s prognosis
Jithma Abeykoon • 5 Dec 2018

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals